COVID-19 treatments: authorised

Treatments authorised in the European Union (EU) to treat COVID-19, following evaluation by the European Medicines Agency (EMA). 

Authorised COVID-19 treatments

The following treatments can be used in the EU to treat COVID-19:

Treatment Status More information
Evusheld (tixagevimab / cilgavimab) Marketing authorisation granted: 25/03/2022 Latest news
Kineret (anakinra) Marketing authorisation granted: 17/12/2021 Latest news
Paxlovid (PF-07321332 / ritonavir) Conditional marketing authorisation granted: 28/01/2022

Latest news

Paediatric investigation plan

RoActemra Marketing authorisation for COVID-19 indication granted: 07/12/2021 Latest news
Veklury (remdesivir)

Marketing authorisation granted: 08/08/2022

Conditional marketing authorisation granted: 03/07/2020

Latest news

Clinical data (login required)

Paediatric investigation plan

Regkirona (regdanvimab) Marketing authorisation granted: 12/11/2021

Latest news

Paediatric investigation plan

Ronapreve (casirivimab / imdevimab) Marketing authorisation granted: 12/11/2021 Latest news
Xevudy (sotrovimab) Marketing authorisation granted: 17/12/2021 Latest news

For more information on how EMA fast-tracks its evaluation of promising potential COVID-19 medicines, see:


How useful was this page?

Add your rating
9 ratings
2 ratings
1 rating
1 rating
36 ratings